Jemperli market seen growing through 2035 on cancer and personalized medicine demand

The Business Research Company says the global market for Jemperli (dostarlimab) is set for steady expansion through 2035, driven by rising cancer incidence, broader immunotherapy use and personalized medicine. North America led in 2025, while Asia-Pacific is projected to grow fastest over the forecast period.

Why it matters: - Jemperli’s market outlook reflects a wider shift toward targeted immunotherapy in cancer care. - Rising cancer rates, more biomarker testing and broader use of combination therapies could expand demand for dostarlimab over the next decade. - The market report points to long-term commercial growth in a category tied to precision oncology and immune checkpoint inhibition.

What happened: - The Business Research Company released an analysis of the Jemperli (dostarlimab) global market for 2026, with forecasts running from 2026 to 2035. - The report says Jemperli market growth has been steady in recent years and is expected to continue between 2024 and 2034. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa.

The details: - Jemperli is a monoclonal antibody that targets the PD-1 receptor and blocks its interaction with ligands. - The drug reactivates the immune system’s ability to detect and destroy cancer cells more effectively. - Jemperli is primarily approved for certain endometrial cancers and non-small cell lung cancer. - The drug is especially relevant for patients with mismatch repair deficiency and other tumor markers linked to response. - Growth is tied to expanded use in additional cancer types and greater adoption of combination therapies. - The report cites increased research funding, more hospitals integrating immunotherapy into treatment protocols and better survival rates as supporting factors. - Broader acceptance of PD-1 inhibitors is listed as a key trend. - Personalized cancer treatment and biomarker testing are also major market drivers. - The Personalized Medicine Coalition reported in February 2024 that the FDA approved 16 new personalized therapies in 2023, including seven cancer drugs. - The report notes that cancer incidence is rising globally because of unhealthy diets, tobacco use, obesity, environmental toxins, screening programs, aging populations and lifestyle changes among younger people. - The Australian Institute of Health and Welfare projected in August 2024 that new cancer diagnoses in Australia will rise from about 169,000 in 2024 to about 209,000 by 2034. - The same projection says cancer will account for about 30% of deaths in Australia in 2024.

Between the lines: - The report frames Jemperli as part of a broader oncology market that is moving toward precision medicine rather than one-size-fits-all treatment. - Regional growth patterns suggest mature markets such as North America remain important, while faster adoption in Asia-Pacific could become the bigger growth engine. - The emphasis on dMMR and MSI-H tumors shows how diagnostic testing is becoming as important as drug access in shaping demand.

What's next: - The market report expects continued expansion as Jemperli reaches more cancer indications and more clinicians adopt combination regimens. - Greater healthcare spending in Asia-Pacific could accelerate regional uptake. - The company added new 2026 report features, including market attractiveness scoring, TAM analysis, company scoring matrix graphics and tables, Excel-based forecasting dashboards, market hotspots infographics, key technologies and future trend analysis, and updated graphics and tables. - The company also offers a free sample report and the full report through its website. - More information is available through the sample request and the full report.